The era of generic weight loss drugs is approaching, and the first batch of patents for GLP drugs have expired, leading to a fierce competition among competitors
影殇·天问
发表于 2024-4-8 18:14:16
3742
0
0
The global weight loss drug market is currently divided into two parts. Novo Nordisk's Wegovy and Ozempic, as well as Eli Lilly's Zepbound and Mounjaro, are the most sought after and effective drugs in the market.
However, both companies are unable to provide drugs to more consumers due to production capacity issues. But this has also made the market for generic weight-loss drugs hot. The industry predicts that by 2030, the market size of GLP generic drugs will reach 100 billion US dollars.
The global patent for Saxenda, the injection of Liraglutide, the main component of Novo Nordisk's previous generation product, will expire in some countries this year. It is also one of the first GLP-1 drugs to lose patent protection. Last February, it had already lost patent protection in the Chinese market.
Compared to Wegovy and Ozempic, Saxenda is now somewhat like "tears of the times" (referring to outdated things), but its efficacy is not enough to make up for in quantity. The influx of generic drug companies will create a strong supply of generic drugs and lower prices, thereby expanding the market.
Among them, Biocon, a leading generic drug company in India, has obtained a license to replicate Saxenda in the UK. The CEO of the company, Siddharth Mittal, confidently stated that his team is ensuring Biocon's leading position in the generic pharmaceutical market. The company has also submitted applications to regulatory agencies in the United States and Europe to replicate the drug Liraglutide.
The future is bright
Weight loss pills have already created record breaking profits for Novo Nordisk and Lilly, which has caught the attention of other pharmaceutical companies, and generic drugs are the key way for them to openly compete for market share.
Biocon is a typical example of this. The company stated that it is building infrastructure to seize strategic opportunities centered around GLP drugs. Liraglutide products are just the beginning, waiting for the expiration of patents for more effective Smegglutide and Tezepamide products. The generic drug market is bound to ignite a greater wave of competition.
Mittal stated that weight loss drugs will be a very attractive market for the next 20 years, and the UK's approval of Biocon's production of generic Liraglutide demonstrates Biocon's ability to seize this opportunity.
There are also leaders in the Chinese market. Last year, the Liraglutide biosimilar developed by East China Pharmaceutical was approved for the treatment of obesity. Hangzhou Jiuyuan Genetic Engineering Co., Ltd. announced last week that it is applying to sell Megglutide generic drugs in China to control the blood sugar of patients with type 2 diabetes.
Jiuyuan Genetic Engineering also pointed out that it cannot commercialize drugs before the patent expires unless a court with jurisdiction determines that the patent is invalid. According to Novo Nordisk's annual report, the patent for its semaglutide drug in China will expire in 2026, while the patent for the European and American markets will expire from 2031 to 2032.
Jiuyuan Gene Factory also emphasized that the Chinese market potential of Smegglutide is enormous, with its scale increasing from 2.5 billion RMB in 2022 to 43.9 billion RMB in 2032, with a compound annual growth rate of up to 33%.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- A milestone breakthrough! Google DeepMind launches a new generation of drug development AI model AlphaFold 3
- Tesla opens a new chapter in its business in China! The first batch of Megapack contracts for the construction of a new energy storage super factory
- Tesla Shanghai Energy Storage Super Factory Starts! Strive to start production and deliver the first batch of Megapacks this year, and have signed a contract
- Lingang Group and Tesla have signed the first batch of orders for Megapack, a super large electrochemical commercial energy storage system, in China
- European drug regulatory agency recommends approval of Dupixen for the treatment of patients with chronic obstructive pulmonary disease
- Tesla: Model 3 High Performance Edition is expected to start its first delivery in mid June
- Tesla: The Model 3 high-performance version is expected to start its first delivery in mid June, starting today
- Up 77%! Tesla sold over 55000 vehicles domestically in May! Model 3 High Performance Edition is about to begin its first batch of deliveries
- The first batch of L3 level intelligent connected vehicle pilot list has been announced! Nine companies including BYD and NIO have been selected, but Huawei and Xiaopeng are nowhere to be seen
- The Federal Reserve's "Eagle Mouth" still exists! Speech by the first batch of officials after the resolution: Whether interest rates can be reduced depends on a few more data points
-
7月23日,联合包裹于周二盘前公布了2024年第二季度财报业绩。数据显示,联合包裹Q2营收为218亿美元,同比下降1.1%,比预期低4.4亿美元,Non-GAAP调整后每股收益为1.79美元,同比下降29.5%,比预期低0.20美元。值 ...
- yagesmlj
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【马斯克最新访谈:“全球最强AI”年底发布 否认给特朗普巨额捐款】当地时间7月23日,特斯拉CEO埃隆马斯克与著名心理学家乔丹彼得森在位于美国得克萨斯州的超级工厂进行了一次深入对话。此次访谈不仅触及了科技前沿 ...
- fengbaox
- 昨天 13:19
- 支持
- 反对
- 回复
- 收藏
-
当地时间7月22日,特斯拉CEO马斯克在社交媒体上表示,明年特斯拉将小规模生产人形机器人,供公司内部使用。2026年,特斯拉有望为其他公司大批量生产机器人。同日,马斯克在社交媒体上宣布,当地时间4时20分,旗 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
欧盟针对原产于中国的天然代糖产品赤藓糖醇反倾销初裁落地,面对31.9%至235.6%不等的税率,市场和投资者直呼“背刺”,同时也对最高7倍的税率差是否会带来洗牌效应产生疑虑。 “作为全球赤藓糖醇消费的重要 ...
- rmamy
- 3 天前
- 支持
- 反对
- 回复
- 收藏